Free Trial

Adial Pharmaceuticals (ADIL) Competitors

Adial Pharmaceuticals logo
$0.36 +0.00 (+1.03%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$0.36 0.00 (-0.44%)
As of 10/24/2025 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ADIL vs. KZR, XCUR, RNTX, SONN, IMA, CVKD, LNAI, ENLV, DARE, and PASG

Should you be buying Adial Pharmaceuticals stock or one of its competitors? The main competitors of Adial Pharmaceuticals include Kezar Life Sciences (KZR), Exicure (XCUR), Rein Therapeutics (RNTX), Sonnet BioTherapeutics (SONN), ImageneBio (IMA), Cadrenal Therapeutics (CVKD), Lunai Bioworks (LNAI), Enlivex Therapeutics (ENLV), Dare Bioscience (DARE), and Passage Bio (PASG). These companies are all part of the "pharmaceutical products" industry.

Adial Pharmaceuticals vs. Its Competitors

Adial Pharmaceuticals (NASDAQ:ADIL) and Kezar Life Sciences (NASDAQ:KZR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

Kezar Life Sciences is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adial PharmaceuticalsN/AN/A-$13.20M-$1.05-0.35
Kezar Life SciencesN/AN/A-$83.74M-$9.69-0.64

Adial Pharmaceuticals currently has a consensus price target of $4.75, suggesting a potential upside of 1,209.98%. Kezar Life Sciences has a consensus price target of $6.00, suggesting a potential downside of 2.60%. Given Adial Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Adial Pharmaceuticals is more favorable than Kezar Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adial Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.60
Kezar Life Sciences
2 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

16.4% of Adial Pharmaceuticals shares are held by institutional investors. Comparatively, 67.9% of Kezar Life Sciences shares are held by institutional investors. 4.3% of Adial Pharmaceuticals shares are held by insiders. Comparatively, 10.4% of Kezar Life Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Kezar Life Sciences had 1 more articles in the media than Adial Pharmaceuticals. MarketBeat recorded 4 mentions for Kezar Life Sciences and 3 mentions for Adial Pharmaceuticals. Adial Pharmaceuticals' average media sentiment score of 0.63 beat Kezar Life Sciences' score of 0.10 indicating that Adial Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Adial Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Kezar Life Sciences
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Adial Pharmaceuticals has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500. Comparatively, Kezar Life Sciences has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500.

Kezar Life Sciences' return on equity of -63.51% beat Adial Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Adial PharmaceuticalsN/A -191.31% -153.59%
Kezar Life Sciences N/A -63.51%-52.13%

Summary

Adial Pharmaceuticals beats Kezar Life Sciences on 9 of the 14 factors compared between the two stocks.

Get Adial Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ADIL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ADIL vs. The Competition

MetricAdial PharmaceuticalsBiotechnology IndustryMedical SectorNASDAQ Exchange
Market Cap$7.83M$219.07M$6.23B$10.66B
Dividend YieldN/A3.81%5.71%4.82%
P/E Ratio-0.353.2830.4330.35
Price / SalesN/A5,399.00594.57134.18
Price / CashN/A13.1937.0161.44
Price / Book0.5790.1312.046.60
Net Income-$13.20M-$90.99M$3.32B$276.82M
7 Day Performance0.75%0.21%1.88%2.53%
1 Month Performance8.34%5.28%7.68%3.71%
1 Year Performance-67.04%495.29%56.01%33.82%

Adial Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ADIL
Adial Pharmaceuticals
3.1823 of 5 stars
$0.36
+1.0%
$4.75
+1,210.0%
-67.0%$7.83MN/A-0.3520Analyst Forecast
KZR
Kezar Life Sciences
3.0013 of 5 stars
$4.30
+0.2%
$9.00
+109.3%
-23.2%$31.81M$7M-0.4560
XCUR
Exicure
1.7647 of 5 stars
$5.02
-1.6%
N/A+114.6%$31.73M$500K-1.2950Gap Up
RNTX
Rein Therapeutics
3.2156 of 5 stars
$1.32
-1.5%
$10.00
+657.6%
N/A$30.77MN/A-0.499
SONN
Sonnet BioTherapeutics
2.2775 of 5 stars
$4.42
+2.6%
$20.00
+352.4%
-21.6%$30.29M$20K0.0010News Coverage
IMA
ImageneBio
3.661 of 5 stars
$7.56
-1.0%
$35.50
+369.6%
-61.0%$30.28M$3.50M-0.9870News Coverage
Analyst Forecast
Gap Up
CVKD
Cadrenal Therapeutics
3.2716 of 5 stars
$14.14
+1.1%
$32.00
+126.3%
-15.7%$28.94MN/A-1.594Analyst Forecast
LNAI
Lunai Bioworks
N/A$1.24
+1.6%
N/AN/A$28.74MN/A-0.1620
ENLV
Enlivex Therapeutics
2.9788 of 5 stars
$1.15
+3.2%
$10.00
+773.4%
-29.9%$27.93MN/A-1.9870
DARE
Dare Bioscience
2.3515 of 5 stars
$2.07
+0.2%
$10.00
+384.3%
-39.7%$27.84M$10K-0.9630Analyst Forecast
PASG
Passage Bio
3.5743 of 5 stars
$8.75
+0.7%
$75.67
+764.8%
-44.7%$27.83MN/A-0.48130

Related Companies and Tools


This page (NASDAQ:ADIL) was last updated on 10/25/2025 by MarketBeat.com Staff
From Our Partners